HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of phenytoin on mood and declarative memory during prescription corticosteroid therapy.

AbstractBACKGROUND:
In humans and animals, corticosteroid excess is associated with impairment in declarative memory and changes in hippocampal structure. In animals, phenytoin pretreatment blocks the effects of stress on memory and hippocampal histology, although no studies have examined the use of phenytoin to prevent corticosteroid-associated memory changes in humans. Mood changes are also common with corticosteroids, but few treatment data are available. This report examines whether phenytoin can prevent mood or declarative memory changes secondary to bursts of prescription corticosteroids.
METHODS:
Thirty-nine patients with allergies or pulmonary or rheumatologic illnesses and given systemic corticosteroid therapy were randomized to receive either phenytoin (300 mg/day) or placebo concurrently with the corticosteroids. Mood was assessed with the Hamilton Rating Scale for Depression, Young Mania Rating Scale, and Activation (ACT) subscale of the Internal State Scale; declarative memory was assessed with the Rey Auditory Verbal Learning Test (RAVLT) at baseline and after approximately 7 days of corticosteroid plus phenytoin or placebo therapy.
RESULTS:
The two groups were similar in age, gender, education, and corticosteroid dose. The phenytoin-treated group showed significantly smaller increases on the ACT, a mania self-report scale, than the placebo-treated group. Groups did not differ significantly on RAVLT change scores.
CONCLUSIONS:
This is the first placebo-controlled study to examine whether a medication can prevent mood and memory changes secondary to corticosteroids. Phenytoin blocked the hypomanic effects of prescription corticosteroids; however, phenytoin did not block the declarative memory effects of corticosteroids.
AuthorsE Sherwood Brown, Gary Stuard, Joshua D M Liggin, Nedim Hukovic, Alan Frol, Nafisa Dhanani, David A Khan, Jala Jeffress, Gregory L Larkin, Bruce S McEwen, Randall Rosenblatt, Yolanda Mageto, Margaret Hanczyc, C Munro Cullum
JournalBiological psychiatry (Biol Psychiatry) Vol. 57 Issue 5 Pg. 543-8 (Mar 01 2005) ISSN: 0006-3223 [Print] United States
PMID15737670 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenal Cortex Hormones
  • Antirheumatic Agents
  • Placebos
  • Phenytoin
Topics
  • Adrenal Cortex Hormones (adverse effects)
  • Adult
  • Affect (drug effects)
  • Antirheumatic Agents (therapeutic use)
  • Case-Control Studies
  • Drug Interactions
  • Drug Prescriptions
  • Female
  • Humans
  • Hypersensitivity (drug therapy, physiopathology)
  • Language Tests (statistics & numerical data)
  • Lung Diseases (drug therapy, physiopathology)
  • Male
  • Memory (drug effects)
  • Memory Disorders (drug therapy, etiology)
  • Middle Aged
  • Mood Disorders (drug therapy, etiology)
  • Neuropsychological Tests (statistics & numerical data)
  • Phenytoin (therapeutic use)
  • Placebos
  • Psychiatric Status Rating Scales
  • Rheumatic Diseases (drug therapy, physiopathology)
  • Verbal Learning (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: